APOA1 and type 2 diabetes mellitus: The addition of evacetrapib to the atorvastatin treatment, beside increasing HDL-C and ApoA-I levels, improved both the ABCA1 and non-ABCA1-mediated CEC of HDL However, the impact of T2DM on the drug response was not specifically investigated [119].